Javascript must be enabled to continue!
Hereditary haemochromatosis
View through CrossRef
Abstract
Hereditary haemochromatosis syndromes are inherited disorders whereby inappropriate absorption of iron by the small intestine leads to iron deposition in the viscera, endocrine organs, and other sites, causing structural injury and impaired function. The most common form is classical adult (HFE-related) haemochromatosis, but other forms are recognized. Extended genetic platforms are increasingly used for specific diagnosis and noninvasive methods are increasingly used to evaluate hepatic damage. The mainstay of treatment is venesection although iron chelation therapy is an emerging oral alternative. Unravelling the molecular genetics of haemochromatosis is underpinning promising new therapies for disorders of iron homeostasis. Classical adult (HFE-related) haemochromatosis: aetiology and pathogenesis—inherited as a recessive trait and due to mutations in the major histocompatibility complex class I-related HFE gene that appear to reduce liver production of hepcidin. The principal mutant allele of HFE, designated C282Y, is carried by approximately 1 in 10 individuals of European ancestry, hence around 1 in 200 are homozygotes, usually with biochemical abnormalities of iron storage that may lead to full-blown clinical haemochromatosis. Clinical features—expression of disease may range from slight abnormalities of blood parameters that reflect iron metabolism to the established clinical syndrome of cutaneous pigmentation, cardiomyopathy, endocrine failure (especially diabetes mellitus and hypogonadism), arthritis, and pigment cirrhosis. Diagnosis—usually established by demonstrating abnormalities of iron metabolism. Molecular analysis of the HFE gene, in particular for homozygosity for the C282Y allele, is confirmatory. Management and prognosis—this is directed to the removal of iron by phlebotomy until the serum ferritin concentration is reduced to within the low normal range, after which the frequency of phlebotomy is reduced. Family members—first-degree relatives should be offered screening.
Oxford University PressOxford
Title: Hereditary haemochromatosis
Description:
Abstract
Hereditary haemochromatosis syndromes are inherited disorders whereby inappropriate absorption of iron by the small intestine leads to iron deposition in the viscera, endocrine organs, and other sites, causing structural injury and impaired function.
The most common form is classical adult (HFE-related) haemochromatosis, but other forms are recognized.
Extended genetic platforms are increasingly used for specific diagnosis and noninvasive methods are increasingly used to evaluate hepatic damage.
The mainstay of treatment is venesection although iron chelation therapy is an emerging oral alternative.
Unravelling the molecular genetics of haemochromatosis is underpinning promising new therapies for disorders of iron homeostasis.
Classical adult (HFE-related) haemochromatosis: aetiology and pathogenesis—inherited as a recessive trait and due to mutations in the major histocompatibility complex class I-related HFE gene that appear to reduce liver production of hepcidin.
The principal mutant allele of HFE, designated C282Y, is carried by approximately 1 in 10 individuals of European ancestry, hence around 1 in 200 are homozygotes, usually with biochemical abnormalities of iron storage that may lead to full-blown clinical haemochromatosis.
Clinical features—expression of disease may range from slight abnormalities of blood parameters that reflect iron metabolism to the established clinical syndrome of cutaneous pigmentation, cardiomyopathy, endocrine failure (especially diabetes mellitus and hypogonadism), arthritis, and pigment cirrhosis.
Diagnosis—usually established by demonstrating abnormalities of iron metabolism.
Molecular analysis of the HFE gene, in particular for homozygosity for the C282Y allele, is confirmatory.
Management and prognosis—this is directed to the removal of iron by phlebotomy until the serum ferritin concentration is reduced to within the low normal range, after which the frequency of phlebotomy is reduced.
Family members—first-degree relatives should be offered screening.
Related Results
Primary Hereditary Haemochromatosis and Pregnancy
Primary Hereditary Haemochromatosis and Pregnancy
Background. Haemochromatosis is a rare autosomal genetic disease that can cause multiple organ failure. In the past, this condition was not considered to affect pregnancy. The obje...
Genotyping as a diagnostic aid in genetic haemochromatosis
Genotyping as a diagnostic aid in genetic haemochromatosis
Background: Two mutations in a newly described gene, HFE, have been proposed as genetic markers for the inherited iron overload disease, genetic haemochromatosis. Methods: We asses...
Haemochromatosis
Haemochromatosis
SummaryHereditary haemochromatosis is the prototype disease for primary iron overload. The disorder is very common, especially amongst subjects of Northern European extraction. It ...
Hereditary haemochromatosis
Hereditary haemochromatosis
Abstract
Hereditary haemochromatosis syndromes are inherited disorders whereby inappropriate absorption of iron by the small intestine leads to iron deposition in...
Original Paper: Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention
Original Paper: Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention
Objectives: Homozygosity for the C282Y mutation of the HFE gene is the main cause of iron overload in hereditary haemochromatosis. This study calculated the number of hepatocellula...
Hereditary haemochromatosis beyond liver cancer: increased risk of prostate cancer during an 11-year follow-up
Hereditary haemochromatosis beyond liver cancer: increased risk of prostate cancer during an 11-year follow-up
AbstractIn European ancestry populations, the iron overload disorder Hereditary Haemochromatosis (HH) is predominantly caused by the HFE p.C282Y mutation. Male p.C282Y homozygotes ...
HFE mutations in patients with hereditary haemochromatosis in Sweden
HFE mutations in patients with hereditary haemochromatosis in Sweden
Cardoso EMP, Stål P, Hagen K, Cabeda JM, Esin S, De Sousa M, Hultcrantz R (Karolinska Hospital, Stockholm; Huddinge University Hospital, Huddinge; and Karolinska Institute, Stockho...
Skin cancer risk in hereditary mixed cancer syndromes
Skin cancer risk in hereditary mixed cancer syndromes
Abstract
Hereditary cancer syndromes are genetic conditions that increase an individual’s risk for multiple cancer types, often due to mutati...

